Reduced-Intensity Allogeneic Stem Cell Transplantation in Children and Young Adults with Ultrahigh-Risk Pediatric Sarcomas

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 5, 2012, Pages 698-707

  Baird, Kristin ^a   Fry, Terry J ^a   Steinberg, Seth M ^a   Bishop, Michael R ^a   Fowler, Daniel H ^a   Delbrook, Cynthia P ^a   Humphrey, Jennifer L ^b   Rager, Alison ^c,d   Richards, Kelly ^a   Wayne, Alan S ^a   Mackall, Crystal L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Allogeneic stem cell transplantation; Pediatric soft tissue sarcoma; Reduced intensity transplantation; Solid tumor

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; HLA ANTIGEN; MELPHALAN; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ADOLESCENT; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CONTINUOUS INFUSION; DESMOPLASTIC SMALL ROUND CELL TUMOR; DONOR; ENGRAFTMENT; EWING SARCOMA; FEMALE; GRAFT RECIPIENT; HUMAN; KAPLAN MEIER METHOD; MALE; MORTALITY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL; PREDICTION; REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANTATION; RHABDOMYOSARCOMA; SARCOMA; SCHOOL CHILD; TREATMENT DURATION;

ADOLESCENT; ADULT; AGE FACTORS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; COHORT STUDIES; FEMALE; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; REMISSION INDUCTION; RISK; SARCOMA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84859813841     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.08.020     Document Type: Article

References (56)

1. McDowell H.P., Foot A.B., Ellershaw C., et al. Outcomes in paediatric metastatic rhabdomyosarcoma: results of The International Society of Paediatric Oncology (SIOP) study MMT-98. Eur J Cancer 2010, 46:1588-1595.
2. Meyers P.A., Krailo M.D., Ladanyi M., et al. High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis. J Clin Oncol 2001, 19:2812-2820.
3. Ladenstein R., Potschger U., Le Deley M.C., et al. Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. J Clin Oncol 2010, 28:3284-3291.
4. Oberlin O., Rey A., Lyden E., et al. Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. J Clin Oncol 2008, 26:2384-2389.
5. Haeusler J., Ranft A., Boelling T., et al. The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES). Cancer 2010, 116:443-450.
6. Carli M., Colombatti R., Oberlin O., et al. European intergroup studies (MMT4-89 and MMT4-91) on childhood metastatic rhabdomyosarcoma: final results and analysis of prognostic factors. J Clin Oncol 2004, 22:4787-4794.
7. McTiernan A.M., Cassoni A.M., Driver D., et al. Improving outcomes after relapse in Ewing's sarcoma: analysis of 114 patients from a single institution. Sarcoma 2006, 2006 83548:1-8.
8. Cotterill S.J., Ahrens S., Paulussen M., et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol 2000, 18:3108-3114.
9. Bacci G., Ferrari S., Bertoni F., et al. Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. J Clin Oncol 2000, 18:4-11.
10. Cotterill S.J., Ahrens S., Paulussen M., et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol 2000, 18:3108-3114.
11. Oberlin O., Deley M.C., Bui B.N., et al. Prognostic factors in localized Ewing's tumours and peripheral neuroectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study). Br J Cancer 2001, 85:1646-1654.
12. Lal D.R., Su W.T., Wolden S.L., et al. Results of multimodal treatment for desmoplastic small round cell tumors. J Pediatr Surg 2006, 40:251-255.
13. Stuart-Buttle C.E., Smart C.J., Pritchard S., et al. Desmoplastic small round cell tumour: a review of literature and treatment options. Surg Oncol 2008, 17:107-112.
14. Schwartz S.I. The James Ewing Lecture. One life, many livers. Ann Surg Oncol 1998, 5:573-579.
15. Burdach S., Jurgens H., Peters C., et al. Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma. J Clin Oncol 1993, 11:1482-1488.
16. Horowitz M.E., Kinsella T.J., Wexler L.H., et al. Total-body irradiation and autologous bone marrow transplant in the treatment of high-risk Ewing's sarcoma and rhabdomyosarcoma. J Clin Oncol 1993, 11:1911-1918.
17. Ladenstein R., Lasset C., Pinkerton R., et al. Impact of megatherapy in children with high-risk Ewing's tumours in complete remission: a report from the EBMT Solid Tumour Registry. Bone Marrow Transplant 1995, 15:697-705.
18. Boulad F., Kernan N.A., LaQuaglia M.P., et al. High-dose induction chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy in rhabdomyosarcoma, extraosseous Ewing's sarcoma, and undifferentiated sarcoma. J Clin Oncol 1998, 16:1697-1706.
19. Kasper B., Lehnert T., Bernd L., et al. High-dose chemotherapy with autologous peripheral blood stem cell transplantation for bone and soft-tissue sarcomas. Bone Marrow Transplant 2004, 34:37-41.
20. Hale G.A. Autologous hematopoietic stem cell transplantation for pediatric solid tumors. Expert Rev Anticancer Ther 2005, 5:835-846.
21. Ek E.T., Choong P.F. The role of high-dose therapy and autologous stem cell transplantation for pediatric bone and soft tissue sarcomas. Expert Rev Anticancer Ther 2006, 6:225-237.
22. Hahn T., Wall D., Camitta B., et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in children: an evidence-based review. Biol Blood Marrow Transplant 2005, 11:823-861.
23. Bishop M.R., Steinberg S.M., Gress R.E., et al. Targeted pretransplant host lymphocyte depletion prior to T-cell depleted reduced-intensity allogeneic stem cell transplantation. Br J Haematol 2004, 126:837-843.
24. Hardy N.M., Hakim F., Steinberg S.M., et al. Host T cells affect donor T cell engraftment and graft-versus-host disease after reduced-intensity hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007, 13:1022-1030.
25. Conrad R., Remberger M., Cederlund K., et al. A comparison between low intensity and reduced intensity conditioning in allogeneic hematopoietic stem cell transplantation for solid tumors. Haematologica 2008, 93:265-272.
26. Carvallo C., Childs R. Nonmyeloablative stem cell transplantation as immunotherapy for kidney cancer and other metastatic solid tumors. Cytotechnology 2003, 41:197-206.
27. Demirer T., Barkholt L., Blaise D., et al. Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors. Nat Clin Pract Oncol 2008, 5:256-267.
28. Ladenstein R., Lasset C., Hartmann O., et al. Comparison of auto versus allografting as consolidation of primary treatments in advanced neuroblastoma over one year of age at diagnosis: report from the European Group for Bone Marrow Transplantation. Bone Marrow Transplant 1994, 14:37-46.
29. Kanold J., Paillard C., Tchirkov A., et al. Allogeneic or haploidentical HSCT for refractory or relapsed solid tumors in children: toward a neuroblastoma model. Bone Marrow Transplant 2008, 42(Suppl 2):S25-S30.
30. Inoue M., Nakano T., Yoneda A., et al. Graft-versus-tumor effect in a patient with advanced neuroblastoma who received HLA haplo-identical bone marrow transplantation. Bone Marrow Transplant 2003, 32:103-106.
31. Hirayama M., Azuma E., Araki M., et al. Evidence of graft-versus-tumor effect in refractory metastatic neuroblastoma. Transplantation 2006, 82:142-144.
32. Lucas K., Schwartz C., Kaplan J. Allogeneic stem cell transplantation in a patient with relapsed Ewing sarcoma. Pediatr Blood Cancer 2008, 51:142-144.
33. Koscielniak E., Gross-Wieltsch U., Treuner J., et al. Graft-versus-Ewing sarcoma: effect and long-term remission induced by haploidentical stem-cell transplantation in a patient with relapse of metastatic disease. J Clin Oncol 2005, 23:242-244.
34. Burdach S., van Kaick B., Laws H.J., et al. Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of the European Intergroup study EICESS. Stem-Cell Transplant Programs at Dusseldorf University Medical Center, Germany and St. Anna Kinderspital, Vienna, Austria. Ann Oncol 2000, 11:1451-1462.
35. Vogelsang G.B., Wagner J.E. Graft-versus-host disease. Hematol Oncol Clin North Am 1990, 4:625-639.
36. Shulman H.M., Sullivan K.M., Weiden P.L., et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980, 69:204-217.
37. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989, 10:1-10.
38. Kaplan E.L., Meiers P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
39. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966, 50:163-170.
40. Agresti A. Categorical Data Analysis 1990, John Wiley & Sons, Inc., New York.
41. Barrett D., Fish J.D., Grupp S.A. Autologous and allogeneic cellular therapies for high-risk pediatric solid tumors. Pediatr Clin North Am 2010, 57:47-66.
42. Whelan J.S., Burcombe R.J., Janinis J., et al. A systematic review of the role of pulmonary irradiation in the management of primary bone tumours. Ann Oncol 2002, 13:23-30.
43. Obeid M., Tesniere A., Ghiringhelli F., et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007, 13:54-61.
44. Apetoh L., Ghiringhelli F., Tesniere A., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007, 13:1050-10509.
45. Ghiringhelli F., Apetoh L., Tesniere A., et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1 beta-dependent adaptive immunity against tumors. Nat Med 2009, 15:1170-1178.
46. Berghuis D., de Hooge A.S., Santos S.J., et al. Reduced human leukocyte antigen expression in advanced-stage Ewing sarcoma: implications for immune recognition. J Pathol 2009, 218:222-231.
47. Borowski A., van Valen F., Ulbrecht M., et al. Monomorphic HLA class I-(non-A, non-B) expression on Ewing's tumor cell lines, modulation by TNF-alpha and IFN-gamma. Immunobiology 1999, 200:1-20.
48. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 363:411-422.
49. Madan R.A., Gulley J.L., Fojo T., et al. Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. Oncologist 2010, 15:969-975.
50. Kantoff P.W., Schuetz T.J., Blumenstein B.A., et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010, 28:1099-1105.
51. Stein W.D., Gulley J., Schlom J., et al. Tumor regression and growth rates determined in five intramural NCI prostate cancer trials. The growth rate as an indicator of therapeutic efficacy. Clin Cancer Res 2011, 17:907-917.
52. Perez-Martinez A., Leung W., Munoz E., et al. KIR-HLA receptor-ligand mismatch associated with a graft-versus-tumor effect in haploidentical stem cell transplantation for pediatric metastatic solid tumors. Pediatr Blood Cancer 2009, 53:120-124.
53. Ahn Y.O., Weigel B., Verneris M.R. Killing the killer: natural killer cells to treat Ewing's sarcoma. Clin Cancer Res 2010, 16:3819-3821.
54. Cutler C., Antin J.H. Sirolimus for GVHD prophylaxis in allogeneic stem cell transplantation. Bone Marrow Transplant 2004, 34:471-476.
55. Cutler C., Henry N.L., Magee C., et al. Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005, 11:551-557.
56. Wan X., Helman L.J. The biology behind mTOR inhibition in sarcoma. Oncologist 2007, 12:1007-1018.